Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
OncoSil Medical's cash receipts from operating activities for the
six
months ended in Dec. 2025 was A$1.16 Mil.
2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.
OncoSil Medical's cash payments for the
six
months ended in Dec. 2025 was A$-8.15 Mil.
3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.
OncoSil Medical's cash payments for the
six
months ended in Dec. 2025 was A$0.00 Mil.
4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.
OncoSil Medical's cash payments for the
six
months ended in Dec. 2025 was A$0.00 Mil.
5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.
OncoSil Medical's cash payments for the
six
months ended in Dec. 2025 was A$-0.02 Mil.
6. Interest Received:
It represents interest received by the company in the direct cash flow method.
OncoSil Medical's cash payments for the
six
months ended in Dec. 2025 was A$0.05 Mil.
7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.
OncoSil Medical's cash payments for the
six
months ended in Dec. 2025 was A$0.00 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).
OncoSil Medical's cash flow from others for the
six
months ended in Dec. 2025 was A$0.00 Mil.
OncoSil Medical Cash Flow from Operations Related Terms
OncoSil Medical Cash Flow from Operations Historical Data
* Premium members only.
The historical data trend for OncoSil Medical's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoSil Medical Cash Flow from Operations Calculation
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
OncoSil Medical's Cash Flow from Operations for the fiscal year that ended in Jun. 2025 is calculated as:
Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-12.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Operations of A$-12.91 Mil mean?
OncoSil Medical (ASX:OSL) has a Cash Flow from Operations of A$-12.91 Mil as of Dec. 2025. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for OncoSil Medical and its competitors.
Is OncoSil Medical's Cash Flow from Operations too high?
OncoSil Medical's current Cash Flow from Operations is A$-12.91 Mil. Overall, OncoSil Medical has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Cash Flow from Operations compare to ABT and SYK?
OncoSil Medical's Cash Flow from Operations of A$-12.91 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Medical Devices & Instruments company?
A good Cash Flow from Operations depends on the Medical Devices & Instruments industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for OncoSil Medical and its competitors. OncoSil Medical's current Cash Flow from Operations is A$-12.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.91, compared to a current price of A$1.45 — trading 50.2% below its estimated fair value. The current Cash Flow from Operations is A$-12.91 Mil. OncoSil Medical's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Cash Flow from Operations is A$-12.91 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoSil Medical (ASX:OSL) Overvalued in 2026?
Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued.
The current stock price of A$1.45 is trading 50.2% below its estimated GF Value™ of A$2.91.
GuruFocus considers OncoSil Medical to be Possible Value Trap.
Key valuation signals for ASX:OSL:
Cash Flow from Operations: A$-12.91 Mil
GF Value™: A$2.91 vs. price of A$1.45 (50.2% below fair value)
No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
46GF Score
Get the complete analysis for ASX:OSL
Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSL has been successfully added to your 
